BLOG

opthalmology times

MEIRAGTX ANNOUNCES DATA FROM PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR PATIENTS WITH X-LINKED RETINITIS PIGMENTOSA

MeiraGTx today announced top-line data from the Phase 1/2 clinical study MGT009 (NCT03252847) of botaretigene sparoparvovec (formerly referred to as AAV-RPGR), an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with disease-causing variants in the RPGR gene.